ProGRP: A new biomarker for small cell lung cancer

European journal of Clinical and Medical Oncology

Volumn 2, Issue 1, 2010, Pages

  Molina, Rafael ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Follow up; Neuroendocrine markers; NSE; ProGRP; Small cell lung cancer (SCLC); Tumor markers

Indexed keywords

CHROMOGRANIN A; CREATINE KINASE; NEURON SPECIFIC ENOLASE; PROGASTRIN RELEASING PEPTIDE; PROSTATE SPECIFIC ANTIGEN; SQUAMOUS CELL CARCINOMA ANTIGEN; SYNAPTOPHYSIN; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER STAGING; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; FALSE POSITIVE RESULT; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NEUROENDOCRINE TUMOR; PREDICTION; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 77956291789     PISSN: 17598958     EISSN: 17598966     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics 2009. CA Cancer J Clin. 2009;59:225-249.
2. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:379-392.
3. Schiller JH. Current standards of care in small-cell and non-small-cell lung cancer. Oncology. 2001;61:3-13.
4. Stupp R, Monnerat C, Turrisi AT, et al. Small cell lung cancer: state of the art and future perspectives. Lung Cancer. 2004;45:105-117.
5. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in nonsmall cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311:899-909.
6. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol.2004; 22:330-353.
7. Mizushima Y, Hirata H, Izumi S, et al. Clinical significance of the number of positive markers in assisting the diagnosis of lung cancer with multiple tumor marker assay. Oncology. 1990;47:43-48.
8. Nisman B, Heching N, Barak V. Serum tumor markers in resectable and non-resectable non-small cell lung cancer. J Tumor Marker Oncol. 2000;15: 195-207.
9. Foa P, Fornier M, Miceli R, et al. Tumor markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Anticancer Res. 1999;19:3613-3618.
10. Paone G, De Angelis G, Munno R, et al. Discriminant analysis on small cell lung cancer and non-small cell lung cancer by means of NSE and CYFRA 21-1. Eur Respir J. 1995;8:1136-1140.
11. Molina R, Auge JM, Bosch X, et al. Mucins CA 125, CA 199, CA 15.3, and TAG 72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE. Tumor Biol. 2008;29:371-380.
12. Molina R, Auge JM, Bosch X, et al. Usefulness of serum tumor markers, including progastrin-releasing peptide in patients with lung cancer: correlation with histology. Tumor Biol. 2009;30:121-129.
13. Barlesi F, Gimenez C, Torre JP, et al. Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer. Respir Med. 2004;98:357-362.
14. Pollan M, Varela G, Torres A, et al. Clinical value of p53, c-erbB-2, CEA and CA 125 regarding relapse, metastases and death in resectable nonsmall cell lung cancer. Int J Cancer. 2003;107:781-790.
15. Sawabata N, Maeda H, Yokota S, et al. Postoperative serum carcinoembryonic antigen levels in patients with pathologic stage IA nonsmall cell lung carcinoma: subnormal levels as an indicator of favourable prognosis. Cancer. 2004;101:803-809.
16. Scheulen ME, Klanig H, Wiefelspÿtz JK, et al. Pre-therapeutic evaluation of cytokeratin fragment 19 (CYFRA 21-1) in 240 patients with lung cancer in comparison to CEA, NSE, SCC-Ag, TPA and TPS. Tumor Diagn Ther. 1997;18:14-19.
17. Niho S, Nishiwaki Y, Goto K, et al. Significance of serum pro-gastrinreleasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen. Lung Cancer. 2000;27:159-167.
18. Shibayama T, Ueoka H, Nishii IK, et al. Complementary roles of progastrin- releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small cell lung cancer (SCLC). Lung Cancer. 2001;32:61-69.
19. Jorgensen LG, Osterlind K, Genolla J, et al. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. Br J Cancer. 1996;74:463-467.
20. Quoix E, Purohit A, Faller-Beau M, et al. Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer. 2000;30:127-134.
21. Lassen U, Osterlind K, Hansen M, et al. Long-term survival in small-cell lung cancer: post treatment characteristics in patients surviving 5 to 18+ years. An analysis of 1714 consecutive patients. J Clin Oncol. 1995;13:1215-1220.
22. Molina R, Filella X, Auge JM. ProGRP: A new biomarker for small cell lung cancer. Clin Biochem. 2004;37:505-511.
23. Molina R, Filella X, Auge JM, et al. Tumour markers (CEA, CA125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as aid in histological diagnosis and prognosis: comparison with the main clinical and pathological prognostic factors. Tumor Biol. 2003;24:209-218.
24. European Group on Tumor Markers. European Group on Tumor Markers: consensus recommendations. Anticancer Res. 1999;19:2785-2820.
25. Stieber P, Dienemann H, Schalhorn A, et al. Pro-gastrin-releasing peptide (ProGRP)-a useful marker in small cell lung carcinomas. Anticancer Res. 1999;19:2673-2678.
26. Stieber P, Dienemann H, Hasholzner U, et al. Tumour associated antigens in the differential diagnosis of lung tumours of unknown origin. Anticancer Res. 1995;15:2389-2393.
27. Plebani M, Basso D, Navaglia F, De Paoli M, Tommasini A, Cipriani A. Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results? Br J Cancer. 1995;72:170-173.
28. Yamaguchi K, Abe K, Kameya T, et al. Production and molecular size heterogeneity of immunoreactive gastrin-releasing peptide in fetal and adult lungs and primary lung tumors. Cancer Res. 1983;43:3932-3939.
29. Lamy PJ, Grenier J, Kramar A, Pujol JL. Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer. Lung Cancer. 2000;29:197-203.
30. Molina R, Alicarte J, Auge JM, et al. Pro-gastrin-releasing peptide (ProGRP) in patients with benign and malignant diseases. Tumor Biol. 2004;25:56-61.
31. Molina R, Auge JM, Filella X, et al. Diagnostic of cancer from unknown origin by using tumor markers: improvement including ProGRP. XII International Symposium on Biology and Clinical Usefulness of Tumor Markers. Barcelona, 2009:32.
32. Stieber P, Yamaguchi K. ProGRP enables diagnosis of small-cell lung cancer. In: Diamandis P, Fritsche HA, Lilja H, Cham DW, Schwartz M, eds. Tumor Markers. Physiology, Pathobiology, Technology and Clinical Applications. Washington, DC: AACC Press;2002:517-521.
33. Okusaka T, Eguchi K, Kasai T. Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. Clin Cancer Res. 1997;3:123-127.
34. Sunaga N, Tsuchiya S, Minato K. Serum pro-gastrin-releasing peptide is a useful marker for treatment monitoring and survival in small-cell lung cancer. Oncology. 1999;6:143-148.
35. Bonner JA, Sloan JA, Rowland KM, et al. Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer. Clin Cancer Res. 2000;6:597-601.
36. Pujol JL, Quantin X, Jacot M, et al. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. Lung Cancer. 2003;39:131-138.
37. Rubins JB, Dunitz J, Rubins HB, et al. Serum carcinoembryonic antigen as an adjunct to preoperative staging of lung cancer. J Thorac Cardiovasc Surg. 1998;116:412-416.
38. Ando S, Suzuki M, Yamamoto N, et al. The prognostic value of both neuron-specific enolase (NSE) and CYFRA 21-1 in small cell lung cancer. Anticancer Res. 2004;24:1914-1916.
39. Takei Y, Minato K, Tsuchiya S, et al. CYFRA 21-1: an indicator of survival and therapeutic effect in lung cancer. Oncology. 1997;54:43-47.
40. Barlesi F, Gimenez C, Torre JP, et al. Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer. Respir Med. 2004;98:357-362.
41. Pollan M, Varela G, Torres A, et al. Clinical value of p53, c-erbB-2, CEA and CA 125 regarding relapse, metastases and death in resectable nonsmall cell lung cancer. Int J Cancer. 2003;107:781-790.
42. Molina R, Galan MC, et al. Tumor markers in response monitoring and prognosis of non-small cell lung cancer: preliminary report. Anticancer Res. 1998;18:631-634.
43. Travis WP, Colby TV, Corrin B, Shimosato Y, Bracambilla E. Histological Typing of Lung and Pleural Tumors. World Health Organization. Berlin: Springer-Verlag; 1999.
44. Schneider J, Phillipp M, Salewski L, Velcovsky HG. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer. Clin Lab. 2003;49:35-42.
45. Takada M, Kusunoki Y, Masuda N, et al. Pro-gastrin-releasing peptide(31-98) as a tumor marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase. Br J Cancer. 1996;73:1227-1232.
46. Johnson PWM, Joel SP; Love S, et al. Tumor markers for prediction of survival and monitoring of remission in small cell lung cancer. Br J Cancer. 1993;67:760-766.